- A small-scale study of AstraZeneca Plc AZN COVID-19 combined with Sputnik Light vaccines has shown robust antibody growth in most of the study's participants, citing the Russian Direct Investment Fund Reuters reported.
- The data was collected from 20 people who took part in a 100-person study in Azerbaijan in February.
- They first received the AstraZeneca shot followed by the one-dose Russian-made Sputnik Light shot 29 days later, RDIF said.
- "According to the results of the interim analysis, a fourfold or higher increase in neutralizing antibodies to the spike protein (S-protein) of the SARS-CoV-2 was found in 85% of the volunteers on the 57th day of the study," RDIF said.
- Price Action: AZN stock closed down 2.70% at $58.72 on Monday.
- Photo by torstensimon from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
